Using Bcr-Abl to examine mechanisms by which Abl kinase regulates morphogenesis in Drosophila

被引:23
|
作者
Stevens, Traci L. [1 ,3 ]
Rogers, Edward M. [1 ]
Koontz, Laura M. [1 ]
Fox, Donald T. [1 ]
Homem, Catarina C. F. [1 ]
Nowotarski, Stephanie H. [1 ]
Artabazon, Nicholas B. [3 ]
Peifer, Mark [1 ,2 ]
机构
[1] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[3] Randolph Macon Coll, Dept Biol, Ashland, VA 23005 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1091/mbc.E07-01-0008
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Signaling by the nonreceptor tyrosine kinase Abelson (Abl) plays key roles in normal development, whereas its inappropriate activation helps trigger the development of several forms of leukemia. Abl is best known for its roles in axon guidance, but Abl and its relatives also help regulate embryonic morphogenesis in epithelial tissues. Here, we explore the role of regulation of Abl kinase activity during development. We first compare the subcellular localization of Abl protein and of active Abl, by using a phosphospecific antibody, providing a catalog of places where Abl is activated. Next, we explore the consequences for morphogenesis of overexpressing wild-type Abl or expressing the activated form found in leukemia, Bcr-Abl. We find dose-dependent effects of elevating Abl activity on morphogenetic movements such as head involution and dorsal closure, on cell shape changes, on cell protrusive behavior, and on the organization of the actin cytoskeleton. Most of the effects of Abl activation parallel those caused by reduction in function of its target Enabled. Abl activation leads to changes in Enabled phosphorylation and localization, suggesting a mechanism of action. These data provide new insight into how regulated Abl activity helps direct normal development and into possible biological functions of Bcr-Abl.
引用
收藏
页码:378 / 393
页数:16
相关论文
共 50 条
  • [11] BCR-ABL kinase dynamics and drug resistance
    Azam, M
    Nardi, V
    Shakespear, WC
    Latek, RR
    Veach, D
    Clarckson, B
    Bohacheck, R
    Sawyer, TK
    Daley, GQ
    BLOOD, 2005, 106 (11) : 565A - 565A
  • [12] BCR-ABL kinase mutations in response to dasatinib
    Khorashad, J. Sorouri
    Mehta, P.
    Milojkovic, D.
    Marin, D. C.
    Kaeda, J. S.
    Swale, B.
    Stevens, D.
    Goldman, J. M.
    Apperley, J. F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 202 - 202
  • [13] Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL monitor assay
    Dufresne, Scott D.
    Belloni, Dorothy R.
    Levy, Norman B.
    Tsongalis, Gregory J.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2007, 131 (06) : 947 - 950
  • [14] Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?
    Yap, E.
    Tumian, N. R.
    Azma, R. Z.
    Sharifah, N. A.
    Salwati, S.
    Hamidah, N. H.
    Elias, M. H.
    Wong, C. L.
    MALAYSIAN JOURNAL OF PATHOLOGY, 2017, 39 (02) : 107 - 113
  • [15] Molecular mechanisms of transformation by the BCR-ABL oncogene
    Sattler, M
    Griffin, JD
    SEMINARS IN HEMATOLOGY, 2003, 40 (02) : 4 - 10
  • [16] Biology of BCR-ABL
    Chopra, R
    Pu, QQ
    Elefanty, AG
    BLOOD REVIEWS, 1999, 13 (04) : 211 - 229
  • [17] ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts - Reply
    Laudadio, Jennifer
    Press, Richard D.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (05): : 476 - 476
  • [18] Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia
    Samanta, A.
    Perazzona, B.
    Chakraborty, S.
    Sun, X.
    Modi, H.
    Bhatia, R.
    Priebe, W.
    Arlinghaus, R.
    LEUKEMIA, 2011, 25 (03) : 463 - 472
  • [19] The immunogenicity of Bcr-Abl-expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl-regulated antigens
    Scheich, Florian
    Duyster, Justus
    Peschel, Christian
    Bernhard, Helga
    BLOOD, 2007, 110 (07) : 2556 - 2560
  • [20] BCR-ABL kinase dynamics in drug resistance.
    Azam, M
    Nardi, V
    Shakespeare, W
    Latek, RR
    Bohacek, R
    Veach, D
    Clarkson, B
    Sawyer, TK
    Daley, GQ
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9021S - 9022S